


RESEARCH ARTICLE

A biomathematical model of immune response and barrier function in mice with pneumococcal lung infection

Sibylle Schirm¹, Peter Ahnert¹, Sarah Berger², Geraldine Nouailles², Sandra-Maria Wienhold², Holger Müller-Redetzky^{2,3}, Norbert Suttorp³, Markus Loeffler¹, Martin Witzenth^{2,3}, Markus Scholz^{1,4*}

1 Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany, **2** Division of Pulmonary Inflammation, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, **3** Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, **4** LIFE Research Center of Civilization Diseases, University of Leipzig, Leipzig, Germany

* markus.scholz@imise.uni-leipzig.de



OPEN ACCESS

Citation: Schirm S, Ahnert P, Berger S, Nouailles G, Wienhold S-M, Müller-Redetzky H, et al. (2020) A biomathematical model of immune response and barrier function in mice with pneumococcal lung infection. PLoS ONE 15(12): e0243147. <https://doi.org/10.1371/journal.pone.0243147>

Editor: Yu-Wei Lin, Monash University, AUSTRALIA

Received: June 4, 2020

Accepted: November 16, 2020

Published: December 3, 2020

Copyright: © 2020 Schirm et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its [Supporting information files](#).

Funding: SS was funded by CAPSyS (“Medical Systems Biology of Pulmonary Barrier Failure in Community Acquired Pneumonia”, grant number 01ZX1304B) and Sympath (“Systems-medicine of pneumonia-aggravated atherosclerosis”, grant number 01ZX1906B). Both research projects are funded by the German Federal Ministry of Education and Research (BMBF) within the

Abstract

Pneumonia is one of the leading causes of death worldwide. The course of the disease is often highly dynamic with unforeseen critical deterioration within hours in a relevant proportion of patients. Besides antibiotic treatment, novel adjunctive therapies are under development. Their additive value needs to be explored in preclinical and clinical studies and corresponding therapy schedules require optimization prior to introduction into clinical practice. Biomathematical modeling of the underlying disease and therapy processes might be a useful aid to support these processes. We here propose a biomathematical model of murine immune response during infection with *Streptococcus pneumoniae* aiming at predicting the outcome of different treatment schedules. The model consists of a number of non-linear ordinary differential equations describing the dynamics and interactions of the pulmonary pneumococcal population and relevant cells of the innate immune response, namely alveolar- and inflammatory macrophages and neutrophils. The cytokines IL-6 and IL-10 and the chemokines CCL2, CXCL1 and CXCL5 are considered as major mediators of the immune response. We also model the invasion of peripheral blood monocytes, their differentiation into macrophages and bacterial penetration through the epithelial barrier causing blood stream infections. We impose therapy effects on this system by modelling antibiotic therapy and treatment with the novel C5a-inactivator NOX-D19. All equations are derived by translating known biological mechanisms into equations and assuming appropriate response kinetics. Unknown model parameters were determined by fitting the predictions of the model to time series data derived from mice experiments with close-meshed time series of state parameters. Parameter fittings resulted in a good agreement of model and data for the experimental scenarios. The model can be used to predict the performance of alternative schedules of combined antibiotic and NOX-D19 treatment. We conclude that we established a comprehensive biomathematical model of pneumococcal lung infection, immune response and barrier function in mice allowing simulations of new treatment schedules. We

framework of the e:Med research and funding concept. MW was funded by the DFG; SFB-TR84, C6 and C9. We acknowledge support from the German Research Foundation (DFG) and University of Leipzig within the program of Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: MS receives funding from Pfizer Inc. for epidemiologic modelling of pneumonia. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The other authors have declared that no competing interests exist.

aim to validate the model on the basis of further experimental data. We also plan the inclusion of further novel therapy principles and the translation of the model to the human situation in the near future.

Introduction

Streptococcus pneumoniae infections are life-threatening especially in children or elderly patients [1]. The disease can rapidly deteriorate within hours requiring immediate intensive care. However, such fulminant disease courses only affect a part of the patient population and it is so far difficult to predict which patients are at high risk.

Besides antibiotic treatment, new adjuvant therapy options are under development. For example the recently developed drug NOX-D19 spiegelmer targets C5a, a component of the complement system responsible for several proinflammatory effects including tissue injury [2]. It was observed in [3] that NOX-D19 reduces lung permeability in mice. Therefore, there is some hope that anti-C5a treatment might help stabilizing barrier function, reducing bacteremia and improving outcome [4]. So far, its relative contribution in combination with antibiotic treatment is not explored.

We recently proposed a biomathematical model of *Streptococcus pneumoniae* infection in mice [5] considering major cellular players of the innate immune response. This model was designed to simulate different schedules of antibiotic treatment. We here propose a significant extension of this work by modelling the barrier function in more detail. We also extend the network of explicitly modelled cytokines and chemokines and propose mechanistic assumptions for the action of NOX-D19 on the system with the aim to simulate combined therapies of antibiotics and NOX-D19. For our modelling, we translated biological knowledge and hypotheses about the key players of the innate immune response and therapy effects into mathematical equations and compare simulation results with available data. For this purpose, we can rely on an extended data base including early time points after infection and NOX-D19 or antibiotic treatment.

Methods

General structure of the model

We revise and extend our recently published model of pneumococcal infection in mice [5] which is based on a model proposed by Smith et al. [6]. Our former model described the dynamics of pneumococci, neutrophils, macrophages, destruction of the epithelial barrier and IL-6 in lung-infected mice using ordinary differential equations. Effects of the antibiotic drugs Moxifloxacin or Ampicillin were included.

Based on new experimental data, we aim at refining this model. First, we now distinguish between alveolar macrophages and inflammatory macrophages, which was impossible on the basis of earlier data. Second, we explicitly model the migration of monocytes from peripheral blood to the alveolar space and their differentiation into inflammatory macrophages. This process is mainly regulated by the cytokines IL-6 and IL-10 and the chemokine CCL2 (MCP-1). Epithelial barrier function is also modeled in more detail to understand, e.g. barrier breakdown and effects of NOX-D19 treatment including their impact on the migration of pneumococci into blood stream. Finally, neutrophil attraction by the chemokines CXCL1 (GRO α) and CXCL5 (LIX, ENA78) is considered. This requires extension of our cytokine / chemokine




Fig 1. Structure of the model. Compartments: pneumococci in lungs (P), pneumococci in peripheral blood (CFUB), unaffected epithelial/endothelial cells (EU), affected epithelial/endothelial cells (EA), alveolar macrophages (AM), inflammatory macrophages (IM), neutrophils (N), monocytes in peripheral blood (MONO), cytokine / chemokine network comprising IL-6, IL-10, CCL2, CXCL1, CXCL5 and TNF α . ABIO denotes the antibiotic therapy. D19 represents the effect of NOX-D19 treatment.

<https://doi.org/10.1371/journal.pone.0243147.g001>

network to be modelled. All model equations are based on biologically motivated hypotheses translated into differential equations. We justify these assumptions and present derived equations in the following. Major compartments and regulations of our model are presented in Fig 1.

Model equations and assumptions

Compartment P: Pneumococci. Healthy mice are infected with pneumococci transnasally. This is modelled in analogy to our former model [5].

$$PneuStart = EffInf \sum_{i=1}^N N \frac{dose_pneu_i}{t_{Pneu}} (Hv(t - \tilde{t}_i) - Hv(t - \tilde{t}_i - t_{Pneu})) \tag{1}$$

where Hv is the Heaviside-function $Hv = \begin{cases} 0 & : x < 0 \\ 1 & : x \geq 0 \end{cases}$, \tilde{t}_i are the time points at which

pneumococci at dose $dose_pneu_i$ are administered in time t_{Pneu} . Here we only consider single infections, i.e. $N = 1$, $\tilde{t}_1 = 0$, $dose_pneu_1 = 5 \cdot 10^6$ and $t_{Pneu} = 1$ min. The infection function is multiplied by a seeding efficacy $EffInf = 0.001$ translating applied amount of bacteria to those in $1\mu l$ of broncho-alveolar lavage (BAL) directly after infection. Measurements two hours after infection are in between 320-2560 CFU/ μl . The factor $EffInf$ indirectly accounts for physical barriers of entry for pathogens, which are assumed to be equal for all animals, and therefore, have no impact on infection dynamics.

Pneumococci population in the alveolar space initially grows with rate k_p until a saturation P_{max} is reached. Bacteria were eliminated by several lines of innate immune defense comprising alveolar macrophages, neutrophils, and finally, inflammatory macrophages [6]. The defense mechanisms are assumed to be saturated by a Michaelis-Menten kinetic representing the limited killing capacity of immune cells. Pneumococci pass the epithelial/endothelial barrier and enter the blood-stream with rate k_{CFUB_P} and in dependence on bacterial load and

permeability of the barrier described by the amount of affected epithelial cells (EA, see below). Antibiotic treatment imposes a time dependent loss rate $A(t)$ on the pneumococci population. Summarizing these assumptions results in the following equation.

$$\begin{aligned} \frac{dP}{dt} = & \text{PneuStart} + k_p \cdot P(t) \cdot \left(1 - \frac{P(t)}{P_{\max}}\right) \\ & - (k_{p_AM} \cdot AM_0 + k_{p_N} \cdot N(t) + k_{p_IM} \cdot IM(t)) \cdot \frac{P(t)}{n + P(t)} \\ & - k_{CFUB_P} \cdot P(t) \cdot EA(t) - A(t) \cdot P(t) \end{aligned} \tag{2}$$

The time dependent antibiotic effect $A(t)$ is modelled by injection functions of antibiotics and a resulting (delayed) effect on pneumococci. First, injections of antibiotic drugs $ABIO^{inj}(t)$ are modelled by a sum of pulse functions which can be written as

$$ABIO^{inj}(t) = \frac{\text{dose}_{ABIO} \cdot k_{ABIO}}{t_{ABIO}} \cdot \sum_{i=1}^N (Hv(t - \tilde{t}_i) - Hv(t - \tilde{t}_i - t_{ABIO})) \tag{3}$$

where \tilde{t}_i are the time points at which antibiotics at a dose of “ dose_{ABIO} ” were administered. k_{ABIO} describes the antibiotic effect of the administered drug, i.e. its toxicity to pneumococci. The duration of the injections (t_{ABIO}) is set to 0.1 hour. The applied dose is normalized to this injection time by the factor $1/t_{ABIO}$.

In analogy to [5], we assume that the antibiotic effect after injection is delayed. This is modelled by two delay compartments with first order transitions, where $C_{ABIO}^{(i)}(t)$ is the concentration of the antibiotic drug in the delay compartment i :

$$\frac{dC_{ABIO}^{(i)}(t)}{dt} = C_{ABIO_out}^{(i-1)}(t) - k_{ABIO}^{Delay} \cdot C_{ABIO}^{(i)}(t) \quad i = 1, 2 \tag{4}$$

with the settings

$$C_{ABIO_out}^{(0)}(t) = ABIO^{inj}(t)$$

and

$$C_{ABIO_out}^{(i)}(t) = k_{ABIO}^{Delay} \cdot C_{ABIO}^{(i)}(t) \quad i = 1, 2$$

$C_{ABIO_out}^{(2)}(t)$ enters the compartment of antibiotic effect on pneumococci:

$$\frac{dA(t)}{dt} = C_{ABIO_out}^{(2)}(t) - d_{ABIO} \cdot A(t) \tag{5}$$

where $A(t)$ corresponds to the antibiotic effect and d_{ABIO} is the waning rate. The antibiotic effect $A(t)$ of repetitive applications is illustrated in Fig 2.

Compartments EU and EA: Unaffected and affected epithelial/endothelial cells. One of the most important possible consequences of lung infection is the destruction of the epithelial/endothelial cells forming the barrier between lung and circulation allowing for gas exchange. In the course of the disease, these cells are damaged, both by attacking pneumococci and by infiltrating immune cells as well. In consequence, the barrier becomes more permeable to cells and molecules. This can further promote systemic infection and inflammation up to sepsis. Similar to our former modeling [5] but in more detail, we incorporate these mechanisms into the model. The compartment EU consists of unaffected epithelial and endothelial cells, which are not distinguished. In the presence of bacteria, unaffected epithelial cells EU are transformed into affected epithelial cells EA with rate parameter k_{EU_P} . Independent of bacteria, we further assume an additional barrier injury caused by neutrophil migration, suicidal




Fig 2. Antibiotic therapy. In this example, the antibiotic effect $A(t)$ of repetitive drug administrations in time intervals of 12 hours is shown. Therapy starts 24 hours after infection and stops after 8 injections.

<https://doi.org/10.1371/journal.pone.0243147.g002>

netosis and other processes [7, 8] with rate parameter k_{EU_N} . Thus

$$\begin{aligned} \frac{dEU(t)}{dt} &= -(k_{EU_P} \cdot P(t) \cdot EU(t) + k_{EU_N} \cdot EU(t) \cdot N(t)) + P_{EU} \\ P_{EU} &= k_{EU_N} \cdot EU_0 \cdot N_0 \end{aligned} \tag{6}$$

As a consequence of the above mentioned mechanisms, even in the disease free steady-state there is a constant loss of epithelial cells which is balanced by the constant production term P_{EU} . This also ensures that the system returns to steady-state after elimination of pneumococci [9].

The compartment EA describes affected epithelial cells and is fed by cells from EU attacked by pneumococci or impaired by neutrophils [7, 8]. The influence of cytokines or other immune cells on EA is neglected. Cells in this compartment were removed with rate d_E . Referring to data and the above mentioned mechanisms, we assume a steady state level $EA_0 > 0$ caused by a constant “production” of such cells P_{EA} .

$$\begin{aligned} \frac{dEA(t)}{dt} &= P_{EA} - d_E \cdot EA(t) + (k_{EU_P} \cdot EU(t) + k_{EU_N} \cdot EU(t) \cdot N(t)) \\ P_{EA} &= d_E \cdot EA_0 - k_{EU_N} \cdot EU_0 \cdot N_0 \end{aligned} \tag{7}$$

NOX-D19 treatment. The complement component C5a is involved in the immune response to infection, but it can also cause hyperinflammation or barrier and organ failure. NOX-D19 Spiegelmer was developed to neutralise C5a [2–4] which is intended to prevent or ameliorate these complications. We include this effect phenomenologically by modifying the flux from EU to EA with a NOX-D19-dose dependent sigmoidal function $ZD19(t)$.

$$\begin{aligned} ZD19(t) &= ZD19_{\max} - (ZD19_{\max} - ZD19_{\min})e(-\ln\left(\frac{ZD19_{\max} - ZD19_{\min}}{ZD19_{\max} - ZD19_{\text{hor}}}\right) \cdot (D19(t))^{ZD19_b}) \end{aligned} \tag{8}$$

$D19(t)$ is set to the dose of NOX-D19 for 24 hours after application, and to zero otherwise. To include this effect, we extend Eqs 6 and 7, accordingly.

$$\frac{dEU(t)}{dt} = -(k_{EU-P} \cdot P(t) \cdot EU(t) + k_{EU-N} \cdot EU(t) \cdot N(t)) \cdot ZD19(t) + P_{EU} \tag{9}$$

$$\begin{aligned} \frac{dEA(t)}{dt} = & (k_{EU-P} \cdot P(t) \cdot EU(t) + k_{EU-N} \cdot EU(t) \cdot N(t)) \cdot ZD19(t) \\ & + P_{EA} - d_E \cdot EA(t) \end{aligned} \tag{10}$$

Compartment CFU-B. With increasing bacterial load and epithelial defects, bacteria or molecules can enter the bloodstream resulting in systemic infection [10–12]. In our model, transition of bacteria from alveolar spaces to blood depends on the number of affected epithelial cells and the amount of bacteria in alveolar spaces coupled by rate parameter k_{CFUB-P} . Passage of bacteria through the barrier is modelled by two delay compartments:

$$\frac{dC_{P-CFUB}^{(i)}(t)}{dt} = C_{P-CFUB_out}^{(i-1)}(t) - k_{P-CFUB}^{Delay} \cdot C_{P-CFUB}^{(i)}(t) \quad i = 1, 2 \tag{11}$$

$$\begin{aligned} C_{P-CFUB_out}^{(i)}(t) &= k_{P-CFUB}^{Delay} \cdot C_{P-CFUB}^{(i)}(t) \quad i = 1, 2 \\ C_{P-CFUB_out}^{(0)}(t) &= k_{CFUB-P} \cdot P(t) \cdot EA(t) \end{aligned}$$

where $C_{P-CFUB_out}^{(0)}(t)$ is the efflux from compartment P and $C_{P-CFUB_out}^{(2)}(t)$ is the influx into the peripheral blood compartment $CFUB$:

$$\frac{dCFUB(t)}{dt} = C_{P-CFUB_out}^{(2)}(t) - d_{CFUB} \cdot CFUB(t) \tag{12}$$

Here, we only assume an unspecific removal of bacteria from blood stream with rate d_{CFUB} , i.e. proliferation of bacteria, action of antibiotic treatment and immune responses are not explicitly modelled in the blood compartment.

Compartment N: Neutrophils. After alveolar macrophage, neutrophils represent the second line of the innate immune response to lung infection. Recruited by pro-inflammatory cytokines and chemokines, they migrate into the alveolar space to eliminate bacteria [7]. As in our former model [5], we assume a positive correlation of neutrophil migration with the cytokine IL-6 saturated by a maximum number N_{max} [6, 13]. N_{max} is set to the highest neutrophil value observed in the experimental group without treatment. Here, we additionally assume a positive correlation with the chemokines CXCL1 and CXCL5 [14]. Neutrophils are lost due to fighting the infection at rate d_{N-P} or by natural cell death at rate dN [6]. A neutrophil count of

N_0 , realized by a baseline recruitment P_N , is assumed as disease-free steady state.

$$\begin{aligned} \frac{dN(t)}{dt} &= (k_{N_IL6} \cdot IL6(t) + k_{N_CXCL5} \cdot CXCL5(t) \\ &\quad + k_{N_CXCL1} \cdot CXCL1(t)) \cdot \left(1 - \frac{N(t)}{N_{max}}\right) \\ &\quad - d_{N_P} \cdot N(t) \cdot P(t) + P_N \\ P_N &= d_N \cdot N_0 - (k_{N_IL6} \cdot IL6_0 + k_{N_CXCL5} \cdot CXCL5_0 \\ &\quad + k_{N_CXCL1} \cdot CXCL1_0) \cdot \left(1 - \frac{N_0}{N_{max}}\right) \end{aligned} \tag{13}$$

Compartment MONO: Blood monocytes. As third line of immune response, monocytes migrate to the alveolar space and differentiate into inflammatory macrophages. These processes are promoted by IL-6 [15] and CCL2 [16]. The antiinflammatory cytokine IL-10 counter-acts monocyte recruitment which is modelled by a dose-dependent inverse Z-function *ZIL10* (see below).

$$\begin{aligned} \frac{dMONO(t)}{dt} &= k_{MONO_IL6} \cdot IL6(t) \cdot ZIL10(t) \\ &\quad - (k_{MONO_IM_IL6} \cdot IL6(t) + k_{MONO_IM_CCL2} \cdot CCL2(t)) \cdot MONO(t) \\ &\quad - d_{MONO} \cdot MONO(t) + P_{MONO} \end{aligned} \tag{14}$$

with steady state condition

$$\begin{aligned} P_{MONO} &= k_{MONO_IM_IL6} \cdot MONO_0 \cdot IL6_0 + d_{MONO} \cdot MONO_0 \\ &\quad - k_{MONO_IL6} \cdot IL6_0 \cdot ZIL10_0 \end{aligned}$$

We assume that monocyte to macrophage differentiation occurs with some time delay modeled by a delay compartment $C_M(t)$:

$$\frac{dC_M(t)}{dt} = C_{MONO_out}(t) - k_{MONO}^{Delay} \cdot C_M(t) \tag{15}$$

with the influx

$$C_{MONO_out}(t) = (k_{MONO_IM_IL6} \cdot IL6(t) + k_{MONO_IM_CCL2} \cdot CCL2(t)) \cdot MONO(t)$$

and the efflux

$$MONO_{out}(t) = k_{MONO}^{Delay} \cdot C_M(t)$$

entering the compartment of inflammatory macrophages IM.

Compartments of alveolar macrophages (AM) and inflammatory macrophages (IM). Alveolar macrophages AM serve as first line of innate immune response [17]. In contrast to our earlier model, an improved data base now allows us to distinguish between alveolar macrophages AM and migrated monocyte derived macrophages IM. Analogous to Smith et al. [6], losses of macrophages due to fighting the infection are neglected. Accordingly, the number of alveolar macrophages is assumed to be constant. However, for the inflammatory macrophages, we assume a reduction rate d_{IM} to allow re-establishment of the disease-free steady state after

successful elimination of the infection.

$$\frac{dIM(t)}{dt} = k_{\text{MONO}} \cdot \text{MONO}_{\text{out}}(t) - d_{\text{IM}} \cdot IM(t) + P_{\text{IM}} \tag{16}$$

with the steady state condition

$$P_{\text{IM}} = d_{\text{IM}} \cdot IM_0 - k_{\text{MONO}} \cdot k_{\text{MONO-IM-IL6}} \cdot IL6_0 \cdot \text{MONO}_0.$$

Compartment IL6: Cytokine IL-6. The cytokine IL-6 is produced by several cells, including affected epithelial cells and macrophages [18, 19]. IL-6 is known for its various proinflammatory effects, for instance its involvement in differentiation, maturation and activation of immune cells [19]. IL-6 serves as the most important mediator of immune response in our model which is based on the following assumptions. IL-6 attracts cells of the immune system (monocytes, neutrophils) and stimulates the differentiation of monocytes into macrophages. It is secreted by affected epithelial cells at rate $k_{\text{IL6-EA}}$ and by alveolar and inflammatory macrophages at rates $k_{\text{IL6-AM}}$ and $k_{\text{IL6-IM}}$, respectively. IL-6 secretion of affected epithelial cells starts immediately, whereas we assume a delayed production of IL-6 by macrophages resulting in slower increase in case of infection and a later stop of production in case of removal of the infection. This is modeled by inserting a delay compartment.

$$\begin{aligned} \frac{dC_{\text{delay-IL6}}(t)}{dt} &= (k_{\text{IL6-AM}} \cdot AM_0 + k_{\text{IL6-IM}} \cdot IM(t)) \cdot P(t) - k_{\text{P}}^{\text{Delay}} \cdot C_{\text{delay-IL6}}(t) \\ C_{\text{delay-IL6}}(0) &= 0 \end{aligned}$$

The efflux $k_{\text{P}}^{\text{Delay}} \cdot C_{\text{delay-IL6}}(t)$ of this compartment enters the compartment IL6. We further assume a constant baseline production P_{IL6} and a first order elimination at rate d_{IL6} .

$$\begin{aligned} \frac{dIL6(t)}{dt} &= k_{\text{IL6-EA}} \cdot EA(t) + k_{\text{P}}^{\text{Delay}} \cdot C_{\text{delay-IL6}}(t) - d_{\text{IL6}} \cdot IL6(t) + P_{\text{IL6}} \\ P_{\text{IL6}} &= d_{\text{IL6}} \cdot IL6_0 - k_{\text{IL6-EA}} \cdot EA_0 \end{aligned} \tag{17}$$

Compartment IL10: Cytokine IL-10. The anti-inflammatory cytokine IL-10 reduces the activity of several immune cells and the production of different proinflammatory cytokines. It is a major down-regulator of the immune response required to stop immune reaction after successfully fighting the infection. Most cells of the immune system are able to produce IL-10 [19, 20]. For our modeling, it is sufficient to assume production by monocytes in peripheral blood with rate $k_{\text{IL10-MONO}}$ and by neutrophils in alveolar spaces with rate $k_{\text{IL10-N}}$. An unspecific elimination with rate d_{IL10} and a constant baseline production P_{IL10} implies a positive level of IL10 at disease-free steady-state.

$$\begin{aligned} \frac{dIL10(t)}{dt} &= k_{\text{IL10-MONO}} \cdot \text{MONO}(t) + k_{\text{IL10-N}} \cdot N(t) - d_{\text{IL10}} \cdot IL10(t) + P_{\text{IL10}} \\ P_{\text{IL10}} &= d_{\text{IL10}} \cdot IL10_0 - k_{\text{IL10-N}} \cdot N_0 - k_{\text{IL10-MONO}} \cdot \text{MONO}_0 \end{aligned} \tag{18}$$

The anti-inflammatory effect of IL-10 on monocytes and CCL2 is modeled by a sigmoidal function multiplied to several terms representing immune response.

$$Z_{IL10} = Z_{IL10_{max}} - (Z_{IL10_{max}} - Z_{IL10_{min}}) \cdot \exp\left(-\ln\left(\frac{Z_{IL10_{max}} - Z_{IL10_{min}}}{Z_{IL10_{max}} - Z_{IL10_{nor}}}\right) \cdot \left(\frac{IL10}{IL10_0}\right)^{Z_{IL10_b}}\right) \quad (19)$$

where different sensitivities Z_{IL10_b} are assumed for monocytes, respectively CCL2.

Compartment TNF α : Tumour necrosis factor TNF- α . The tumour necrosis factor TNF- α is another major cytokine of immune response with various pro-inflammatory effects. It is secreted mainly by macrophages [19]. Therefore, we decided to include TNF- α into our model as a potent marker of the third line of immune response and to compare it with available data. To limit the complexity of the model, the multiple effects of TNF- α on other components of the immune system are neglected, i.e. TNF α serves as an outcome parameter of our model with no feedback to other state variables. Again, a delayed production is assumed. Parameters are set to those of IL-6 for model parsimony.

$$\begin{aligned} \frac{dC_{delayTNF\alpha}(t)}{dt} &= (k_{TNF\alpha-AM} \cdot AM_0 + k_{TNF\alpha-IM} \cdot IM(t)) \cdot P(t) - k_P^{Delay} \cdot C_{delayTNF\alpha}(t) \\ C_{delayTNF\alpha}(0) &= 0 \end{aligned} \quad (20)$$

The efflux $k_{delayP} \cdot C_{delayTNF\alpha}(t)$ of this compartment enters the compartment TNF α .

$$\begin{aligned} \frac{dTnf\alpha(t)}{dt} &= k_{TNF\alpha-EA} \cdot EA(t) + k_{delayP} \cdot C_{delayTNF\alpha}(t) - d_{TNF\alpha} \cdot TNF\alpha(t) + P_{TNF\alpha} \\ P_{TNF\alpha} &= d_{TNF\alpha} \cdot TNF\alpha_0 - k_{TNF\alpha-EA} \cdot EA_0 \end{aligned} \quad (21)$$

Compartment CCL2: Monocyte chemoattractant protein-1 (MCP-1). Monocyte chemoattractant protein-1 (MCP-1, CCL2) stimulates the migration of monocytes to the site of inflammation [21]. We assume CCL2 to be produced by the recruited monocytes [16], triggered by affected epithelial cells at rate k_{CCL2_MONO} . The contribution of other cell types to CCL2 production is neglected. IL-10 suppresses the production of CCL2 as modeled by the sigmoidal function $ZIL10(t)$ (see above).

$$\frac{dCCL2(t)}{dt} = k_{CCL2_MONO} \cdot MONO(t) \cdot \left(\frac{EA(t)}{EA_0} - 1\right) \cdot ZIL10(t) - d_{CCL2} \cdot CCL2(t) \quad (22)$$

with $CCL2(0) = 0$.

Compartment CXCL1: Chemokine (C-X-C motif) ligand 1 (GRO α). The chemokine CXCL1 (GRO α) attracts neutrophils and is of high importance in the murine immune response [22]. It is produced by affected epithelial cells, neutrophils and macrophages [14, 23]. The production by macrophages is assumed to be delayed in analogy to IL-6 or IL-10

production:

$$\begin{aligned} \frac{dC_{\text{delayCXCL1}}(t)}{dt} &= (k_{\text{CXCL1-AM}} \cdot AM_0 + k_{\text{CXCL1-IM}} \cdot IM(t)) \cdot P(t) \\ &\quad - k_{\text{P}}^{\text{Delay}} \cdot C_{\text{delayCXCL1}}(t) \\ C_{\text{delayCXCL1}}(0) &= 0 \end{aligned} \tag{23}$$

This results in the following balance equation for CXCL1.

$$\begin{aligned} \frac{dCXCL1(t)}{dt} &= k_{\text{CXCL1-EA}} \cdot EA(t) + k_{\text{CXCL1-N}} \cdot N(t) \\ &\quad + k_{\text{P}}^{\text{Delay}} \cdot C_{\text{delayCXCL1}}(t) - d_{\text{CXCL1}} \cdot CXCL1(t) + P_{\text{CXCL1}} \\ P_{\text{CXCL1}} &= d_{\text{CXCL1}} \cdot CXCL1_0 - k_{\text{CXCL1-EA}} \cdot EA_0 - k_{\text{CXCL1-N}} \cdot N_0 \end{aligned} \tag{24}$$

Compartment CXCL5: Chemokine (C-X-C motif) ligand 5 (LIX, ENA78). The chemokine CXCL5 (LIX, ENA78) attracts neutrophils and it is one of the most dominant chemokines in the mouse [14]. CXCL5 is produced exclusively by affected epithelial cells. Thus, it represents epithelial activation [14, 24, 25].

$$\begin{aligned} \frac{dCXCL5(t)}{dt} &= k_{\text{CXCL5-EA}} \cdot EA(t) - d_{\text{CXCL5}} \cdot CXCL5(t) + P_{\text{CXCL5}} \\ P_{\text{CXCL5}} &= d_{\text{CXCL5}} \cdot CXCL5_0 - k_{\text{CXCL5-EA}} \cdot EA_0 \end{aligned} \tag{25}$$

Compartment D: Debris. Apoptotic neutrophils, eliminated bacteria and affected epithelial cells are summarized as debris [6] contributing with rates $k_{\text{D-N}}$, $k_{\text{D-N-P}}$ and $k_{\text{D-EA}}$, respectively. Debris is reduced with constant rate d_{D} . In our data, debris is measured as histological semi-quantitative score evaluating purulent and catarrhalic pneumonia, perivascular edema, alveolar edema, and inflammation of pleura and mediastinal adipose tissue [26].

$$\frac{dD(t)}{dt} = k_{\text{D-N-P}} \cdot N(t) \cdot P(t) + k_{\text{D-N}} \cdot N(t) + k_{\text{D-EA}} \cdot EA(t) - d_{\text{D}} \cdot D(t) \tag{26}$$

with

$$d_{\text{D}} = \frac{k_{\text{D-N}} \cdot N_0 + k_{\text{D-EA}} \cdot EA_0}{D_0}$$

In our model, debris serves as an outcome parameter not affecting other compartments.

Numerical methods for simulation

Differential equations are implemented in MATLAB 7.5.0.342 (R2007b) using the SIMULINK toolbox (The MathWorks Inc., Natick, MA, USA). Numerical solutions of the equation system are obtained using the variable step solver from Adams and Bashford (ode113, SIMULINK toolbox).

Data

Model simulations are compared with comprehensive data from mice experiments comprising time series of pneumococci, measured as colony-forming units in blood and BAL, neutrophils, alveolar and inflammatory macrophages in BAL, IL-6, TNF- α , IL-10, CCL2 (MCP-1), CXCL5

(LIX, ENA78), and CXCL1 (GRO α) measured in bronchoalveolar lavage fluid (BALF) and barrier function (measured by the ratio of murine serum albumin (MSA) in BALF and serum/plasma). In the antibiotics experiments, data of time points without antibiotic treatment were pooled across experimental groups.

Experiments. All animal studies have been ethically reviewed and approved by the animal ethics committee of Charité—Universitätsmedizin Berlin and local governmental authorities (Landesamt für Gesundheit und Soziales Berlin).

Mice were transnasally inoculated with $5 \cdot 10^6$ colony-forming units (CFUs) of *Streptococcus pneumoniae* (serotype 3, strain PN36, NCTC 7978). In the antibiotics experiments, starting at 24 h or 48 h p.i., ampicillin (0.4 mg/mouse corresponding to 0.02mg/g body weight) was injected intraperitoneally every 12 h (see [27]). A detailed description of the pneumococcal pneumonia model and corresponding data of antibiotic experiments are published in [26].

For C5a neutralization, mice were injected intraperitoneally with anti-C5a L-RNA-aptamer NOX-D19 (20mg/kg or 2mg/kg) or solvent (5% glucose) at the time of infection (0h) and 24 h post infection. This dose was chosen on the basis of pharmacokinetic data of NOX-D20, which is similar to NOX-D19 [4]. The dose of 2mg/kg showed no reduction in pulmonary permeability. Therefore, the dose of 20mg/kg was considered primarily. Treatment with NOX-D19 did not affect leukocyte counts in alveolar spaces and blood, cytokine levels in BALF and blood besides lower G-CSF levels in blood 48h post infection. NOX-D19 had no impact on the bacterial load in alveolar spaces, spleen, liver and blood. A detailed description of these data has been published separately [3].

Mice were euthanized 24h or 48h post infection. Sham infected mice were euthanized 24h post sham infection. Pulmonary permeability was assessed by diffusion of intravenously injected human serum albumin into the alveolar space as described previously [28]. Neutrophil, macrophage, and lymphocyte counts were determined in BAL, neutrophil, monocyte and lymphocyte counts were determined in blood. Cytokine levels in BALF and blood were analyzed by multiplex ELISA technique as described previously [27].

Comparison of model compartments and measured quantities. To compare model and data, we used appropriate counter parts of measured features and simulated model compartments (see Table 1).

Steady state values are derived from the data by calculating geometric means of initial values over all experimental groups (see Table in S1 File).

Table 1. Data and corresponding model compartments.

model compartment	experimental read-out
P (pneumococci)	pneumococci in BAL
CFUB (pneumococci)	pneumococci in blood
IL-6 (cytokine)	IL-6 measured in BALF
IL-10 (cytokine)	IL-10 measured in BALF
TNF α	TNF- α measured in BALF
CCL2	CCL2 measured in BALF
CXCL1	CXCL1 measured in BALF
CXCL5	CXCL5 measured in BALF
N (neutrophils)	neutrophils in BAL
AM (macrophages)	alveolar macrophages in BAL
IM (macrophages)	inflammatory macrophages in BAL
MONO (monocytes)	monocytes in blood
EA (affected epithelial cells)	proxied by ratio BALF/serum albumine

<https://doi.org/10.1371/journal.pone.0243147.t001>

Estimation of parameters

Model calibration is performed by optimizing the agreement of simulation results and data applying the following goal function.

$$\sum_{j=1}^L \left(\frac{f_{\text{model}}(t_j, \mathbf{k}) - f_{\text{data}}(t_j)}{\sigma_j} \right)^2 \rightarrow \min_{\mathbf{k}}, \quad (27)$$

Here, $f_{\text{model}}(t, \mathbf{k})$ represents the solution of the differential equation system with the parameter set $\mathbf{k} = k_1, \dots, k_n$ at time points t_j supported by data, and $f_{\text{data}}(t_j)$ are means of measured values at time $t_j, j = 1, \dots, L$, with corresponding standard deviation σ_j . The left hand side of Eq (27) is referred as the fitness function in the following. Simultaneous fitting of different data sets is achieved by adding respective fitness functions.

To solve the optimization problem, we relied on (1+3)-evolutionary-strategies with self-adapting mutation step size (see [29, 30]) as in our previous work [5]. We initially fitted single differential equations to reduce the number of simultaneous parameter fittings. This is achieved by imposing data curves of coupled state variables rather than model curves. In the next step, we coupled all equations and refined the parameter estimation.

A list of the estimated parameters can be found in S2-S4 Tables in [S1 File](#).

Results

General model behavior

We first performed simulations of different initial bacterial loads without treatments to study the general model behaviour. In case of low initial load, bacteria are successfully eliminated by the immune system, and the model returns to its steady state. Higher doses of bacteria result in more severe infections, and eventually, the system fails to eliminate the infection. Results are displayed in [Fig 3](#).

Parameter sensitivity

Our model contains 66 parameters without therapy and 9 intervention-related parameters. 50 of these parameters (45 of the baseline model, five intervention-related) were identified by fitting the predictions of the model to available data, while the other parameters are set either to known values or to plausible values in case of low identifiability. Fitted parameters were subjected to a comprehensive sensitivity analysis. For this purpose, we evaluated deteriorations of the fitness function when changing single parameter values by $\pm 10\%$ keeping the other parameters constant (see [S1 Fig](#) in [S1 File](#)).

The most sensitive parameters are the initial growth rate of bacteria (k_p), the degradation rate of CCL2 (d_{CCL2}), the contribution to debris from epithelial cells and neutrophils (k_{DEA} , k_{DN}), the migration rate of bacteria through the epithelial barrier (k_{CFUB_P}), the removal of macrophages (d_{IM}), and the neutrophil recruitment rate by IL-6 ($k_{\text{N}_{\text{IL6}}}$).

The sensitivity of monocyte recruitment suppression by IL-10 ($ZIL10_MONO_b$) and the production rates of CXCL1 by macrophages and neutrophils ($k_{\text{CXCL1}_{\text{IM}}}$, $k_{\text{CXCL1}_{\text{N}}}$) are the parameters with lowest sensitivity.

Similar results were obtained when considering other measures of parameter sensitivity. We analysed the impact of relative changes of model parameters on the fitness function. This reveals, for example, that for certain parameters (e.g. k_{DN} , d_{IL10}) only upper or lower bounds are well identifiable (see [S2 Fig](#) in [S1 File](#)). We also simulated the certainty of model predictions if parameters are sampled with a 10% variance (see [S3, S4 Figs](#) in [S1 File](#)).




Fig 3. Model behaviour in dependence on initial bacterial load. We present simulation results of infections with $8 \cdot 10^2$ (dotted line) respectively $9 \cdot 10^2$ (solid line) seeded *Streptococcus pneumoniae* without treatment. Time series of pneumococcal population in BAL (a) and blood (b), neutrophils in BAL (c), inflammatory macrophages in BAL (d), barrier function (e), TNF- α in BALF (f), IL-6 in BALF (g), CCL2 in BALF (h) and IL-10 in BALF (i) are displayed. The lower infectious dose results in cure while the larger infectious dose leads to disseminated disease.

<https://doi.org/10.1371/journal.pone.0243147.g003>

Comparison of model and data

Parameter estimates resulted in a good agreement of model and data for the majority of time points. In Fig 4, the simulated time courses of pneumococcal population in BAL and blood, neutrophils and inflammatory macrophages in BAL, TNF- α , IL-6, CCL2, IL-10, CXCL1 and




Fig 4. Comparison of model and data for a scenario of infection with $5 \cdot 10^6$ *Streptococcus pneumoniae* without treatment. Time series of pneumococcal population in BAL (a) and blood (b), neutrophils in BAL (c), inflammatory macrophages in BAL (d), barrier function (e), histologic score (f), TNF- α in BALF (g), IL-6 in BALF (h), CCL2 in BALF (i), IL-10 in BALF (j), CXCL1 in BALF (k) and CXCL5 in BALF (l) without antibiotic treatment are displayed. The solid black curve represents simulation results. Circles represent data points. In this scenario, the immune system is not able to remove the infection resulting in increasing numbers of immune cells, pro-inflammatory cytokines, barrier failure and bacteremia.

<https://doi.org/10.1371/journal.pone.0243147.g004>




Fig 5. Infection with $5 \cdot 10^6$ *Streptococcus pneumoniae* treated with ampicillin (0.4 mg/mouse) every 12h, starting at 24h. We compare results of model simulation with data under antibiotic treatment. Time series of pneumococcal population in BAL (a) and blood (b), neutrophils in BAL (c), inflammatory macrophages in BAL (d), barrier function (e), histologic score (f), TNF- α in BALF (g), IL-6 in BALF (h), CCL2 in BALF (i), IL-10 in BALF (j), CXCL1 in BALF (k) and CXCL5 in BALF (l) are displayed. The solid black curve represents simulation results. Blue circles represent data. Red dots represent the time points of antibiotic treatment. Treatment results in eradication of bacteria from alveolar spaces and blood. Immune cells, cytokine levels and barrier function also normalize except for macrophages staying elevated during observation period.

<https://doi.org/10.1371/journal.pone.0243147.g005>

CXCL5 in BALF, barrier function, and the histologic score after infection with $5 \cdot 10^6$ *Streptococcus pneumoniae* without treatment are presented and compared with corresponding data. In this experimental scenario, the murine immune system is not able to successfully fight the infection and most animals had to be euthanized after 48h. Accordingly, data and corresponding simulations show that bacteria, cytokine levels and immune cell levels continuously rise or remain on high levels over the observation period of 48 hours. The barrier function (EA) deteriorates quickly after onset of infection and remains impaired over the observation period. Correspondingly, bacteremia shows a similar dynamics.

Next, we studied scenarios with antibiotic treatment. Figs 5 and 6 show corresponding comparisons of model simulations and data after infections with $5 \cdot 10^6$ bacteria under treatment with ampicillin (0.4 mg/mouse) every 12 hours, either starting 24 hours or 48 hours after infection. In both scenarios, bacteria are eradicated and immune cell numbers and cytokine levels normalize. Numbers of bacteria in lung and blood are quickly reduced within three, respectively four days. Cytokine levels normalize within three to seven days, where IL-10 and CCL2 react with the largest delay. Neutrophil counts in lung are predicted to reach steady-state values after about four or five days. Normalization of macrophage counts is achieved much later. These predictions could be experimentally validated on the basis of longer time series.

We then studied the effects of NOX-D19 treatment. Two dose levels (low dose: 2 mg/kg, high dose: 20 mg/kg) were considered. NOX-D19 was applied directly at the time of infection and 24 hours later [2]. Figs 7 and 8 show comparisons of model simulations and data for these scenarios. NOX-D19 alone is insufficient to eliminate the disease but stabilizes the barrier function compared to no treatment.




Fig 6. Infection with $5 \cdot 10^6$ *Streptococcus pneumoniae* treated with ampicillin (0.4 mg/mouse) every 12h, starting at 48h. We compare results of model simulation with data under antibiotic treatment. Time series of pneumococcal population in BAL (a) and blood (b), neutrophils in BAL (c), inflammatory macrophages in BAL (d), barrier function (e), histologic score (f), TNF- α in BALF (g), IL-6 in BALF (h), CCL2 in BALF (i), IL-10 in BALF (j), CXCL1 in BALF (k) and CXCL5 in BALF (l) are displayed. The solid black curve represents simulation results. Blue circles represent data. Red dots represent the time points of antibiotic treatment. Dynamics of state parameters are similar to that of antibiotic treatment starting at 24h but with some delay.

<https://doi.org/10.1371/journal.pone.0243147.g006>

Model prediction

After calibrating the model, we now demonstrate how it can be used for prediction purposes. Since no data of combined antibiotic and NOX-D19 therapy are available, we simulate such




Fig 7. (Treatment with 2 mg/kg NOX-D19). We compare results of model simulation (solid black curve) with data under 2 mg/kg NOX-D19 treatment. Time series of pneumococcal population in BAL (a) and blood (b), neutrophils in BAL (c), IL-6 in BALF (d), barrier function (e) and IL-10 in BALF (f) are displayed. Circles represent data points [2]. NOX-D19 is applied 0 and 24 hours after infection. NOX-D19 treatment alone does not help to eradicate the disease but stabilizes the barrier function.

<https://doi.org/10.1371/journal.pone.0243147.g007>




Fig 8. (Treatment with 20 mg/kg NOX-D19). We compare results of model simulation (solid black curve) with data under 20 mg/kg NOX-D19 treatment. Time series of pneumococcal population in BAL (a) and blood (b), neutrophils in BAL (c), IL-6 in BALF (d), barrier function (e) and IL-10 in BALF (f) are displayed. Circles represent data points [2]. NOX-D19 is applied 0 and 24 hours after infection. NOX-D19 alone is insufficient to eradicate the disease but stabilizes the barrier function.

<https://doi.org/10.1371/journal.pone.0243147.g008>

scenarios for later validation by experimental studies. In detail, we combine the antibiotic treatments studied above with the 20 mg/kg NOX-D19 treatment given 0 and 24 hours after infection. The antibiotic therapy eradicates pneumococci in the lung. Additional application of 20 mg/kg D19 is predicted to result in approximately 45% improvement of barrier function and 10% reduction in bacteremia as determined on the basis of the respective extreme values within the first 48h (see S5 Table in S1 File). After stopping NOX-D19 therapy, barrier destruction continues. Overall, best outcome is achieved by combining 20 mg/kg NOX-D19 with antibiotic treatment started at 24 hours (see Fig 9).

Discussion

Understanding disease dynamics and underlying patho-mechanisms is of utmost importance to improve outcome of pneumonia therapy. In addition to antibiotic therapy, novel adjunctive treatments are under development such as anti-C5a, trimodulin and vasculotide among others [3, 31, 32]. However, so far the most promising therapy schedule for a specific clinical situation is not known, for example how to combine antibiotics with adjunctive treatments. To support this developmental process, we here propose a biomathematical model of mechanisms of lung infection, immune responses, barrier function and therapy actions. The model allows predictions of therapy outcome for yet untested therapy options which could be used to select optimized schedules to be tested in follow-up experiments.

Based on improved experimental data and experiments with the novel anti-C5a drug NOX-D19, we comprehensively revised and extended our previously proposed model of lung infection with *Streptococcus pneumoniae* [5]. This model described dynamics of pneumococci population in lung and resulting innate immune response comprising neutrophils and macrophages in analogy to the model of Smith et al. [6], and additionally, the effects of antibiotic treatment. Due to lack of specific data, in our former model it was impossible to distinguish between alveolar macrophages and macrophages derived from invasive monocytes. IL-6 was




Fig 9. Prediction scenarios. We simulated the outcome of combined 20 mg/kg NOX-D19 and antibiotic treatment starting 24h (green dashed line) or 48h (blue dashed line) after infection and compared the results with no treatment (black solid line), antibiotic treatment alone 24h (green solid line) or 48h (blue solid line) after infection or 2 mg/kg (red solid line) respectively 20 mg/kg (red dashed line) NOX-D19 alone. Time series of pneumococcal population in BAL (a) and blood (b) and barrier function (c) are displayed. Cure is only achieved in scenarios with antibiotic treatment. Bacteremia is smallest in case of 20 mg/kg NOX-D19 combined with early antibiotic treatment.

<https://doi.org/10.1371/journal.pone.0243147.g009>

considered as the major regulator of the immune response. No other cytokines or chemokines were considered.

We now improved this model by adding further important components of the immune response to make it biologically more plausible and to account for the refined data base available to us. First, we now distinguish between alveolar macrophages as a very early line of defense and the lately reacting monocyte-derived macrophages resulting in more realistic dynamics of the contributions of both lines of defense. We extended the network of cytokines and chemokines by adding IL-10 as a major immune-suppressive cytokine responsible for achieving steady-state values after successfully fighting the infection. We newly introduced a chemokine network to model migration of immune cells. In detail, we added CCL2, CXCL1 and CXCL5 which are major factors in murine immune response. Their biological functions are relatively well understood to allow mechanistic modelling [22, 33, 34]. To model treatment with NOX-D19, we put some emphasis on a refined model of barrier function and related extend of bacteremia, i.e. we modeled the transition of bacteria from alveolar tissue to blood stream in dependence on barrier function.

The resulting model is considerably more complex compared to the previous one. Calibrating this model was possible on the basis of an improved data base. Specifically, we now had access to much more closely meshed time points in the early phase after infection. While in the former modelling, we only relied on measurement points at 24h or later, we now had additional measurement points at 2h, 6h and 12h at our disposal. This early phase is characterized by rapid dynamics which are highly informative for model calibration. Moreover, improved experimental read-outs of the barrier function (i.e. serum to BALF albumin ratio and additional cytokines) allowed us to derive refined parameter estimates of the corresponding model compartments. Finally, TNF- α served as another outcome parameter of the model. Thus, experimental readouts of all state parameters of the model were available except for debris for which we used a semi-quantitative histologic score. As a consequence, most of the model

parameters expressed good identifiability. However, there are also some issues regarding data quality: First, without antibiotics a few subjects were euthanized prematurely due to severe disease conditions, resulting in a survival bias affecting measurements at later time points. Second, low cytokine values typically showed larger measurement errors resulting in less precise data at the end of the measurement period for cured subjects. Finally, inter-individual variances in data are relatively high, covering orders of magnitude in a few occasions.

Besides modelling antibiotic treatment, we proposed a semi-mechanistic model of NOX-D19 action in mice for the first time by assuming a reduced damaging effect of invading immune cells on epithelium preventing barrier failure to some extent. Due to the different mechanisms of action of antibiotics and NOX-D19, we assumed independent effects. Accordingly, the drugs act synergistically but not additively due to the strong non-linearity of our model. It needs to be acknowledged that data under NOX-D19 treatment were much sparser, i.e. the early time points were not available for these experiments. Moreover, no data of combined NOX-D19 and antibiotic treatment were available. We used our model to predict the effects of such combination therapies offering a way to validate the model on the basis of future experiments.

Results of model simulations are in good agreement with the experimental data. However, parameters of the model are chosen in such a way that only two final states are possible (disease free and disseminated disease). States with a persistent residual infection are not covered. This might explain the slightly inferior agreement of model and data at late time points in the scenarios with antibiotic treatment.

A limitation of our model is that it is specifically developed for the situation of pneumonia induced by *Streptococcus pneumoniae*. Although this is by far the most frequent cause of the disease (up to 50% [35]) pneumonia may be caused by other bacterial and notably also non-bacterial pathogens such as viruses and fungi. It is not straightforward to generalize our model to these pneumonia pathogens, especially due to substantial differences in immune responses including expression of cytokine networks [36]. Modelling other pathogens would require other model structures as proposed in the literature (e.g. influenza: [37], fungal: [38, 39]). A model of pneumonia caused by *Acinetobacter baumannii* is presented by Diep et al. [40]. This model is based on rat data and describes bacterial population, neutrophils, albumin, and neutrophil-regulated cytokines and chemokines. Macrophages are not considered. Another model was proposed by Mochan et al. [41]. They considered dynamics of *Streptococcus pneumoniae* in lung and blood, neutrophil response and barrier damage but no cytokines or chemokines. Similarly, these players are also considered in the model of Domínguez-Hüttinger et al. [42], who modeled barrier failure in more detail by considering switch activating Toll-like receptors. Exponential growth and elimination of bacteria by the immune system in the blood vessels are included, and sepsis as well as immunological scarring are simulated. Although we considered bacteremia in our model, our model does not cover conditions of pneumogenic sepsis, i.e. a fulminant systemic immune reaction due to lung infection. This would require additional model extensions such as pathogen amplification and immune response in blood.

In conclusion, we proposed a comprehensive biomathematical model of *Streptococcus pneumoniae* including three lines of innate immune response, major cytokine effects, barrier function and effects of treatment including antibiotic therapy and adjunctive treatment with the experimental NOX-D19 spiegelmer therapy. The model was compared with a comprehensive set of experimental data with closely meshed time series in the early phase of infection, with or without treatment. We demonstrated utility of the model for making predictions regarding new therapy schedules. We plan to verify these predictions by future experiments and to extend the model by further therapeutic drugs and strategies.

Supporting information

S1 File. A biomathematical model of immune response and barrier function in mice with pneumococcal lung infection—Supplement material. The file contains estimated model parameters and corresponding sensitivity analyses.
(PDF)

S2 File. A biomathematical model of immune response and barrier function in mice with pneumococcal lung infection—Data used for model development. The file contains observed values.
(TXT)

Author Contributions

Conceptualization: Norbert Suttorp, Markus Loeffler, Markus Scholz.

Data curation: Sarah Berger, Geraldine Nouailles, Sandra-Maria Wienhold, Holger Müller-Redetzky, Martin Witzzenrath.

Funding acquisition: Norbert Suttorp, Markus Loeffler, Markus Scholz.

Investigation: Sibylle Schirm, Markus Scholz.

Methodology: Markus Scholz.

Project administration: Peter Ahnert, Norbert Suttorp, Markus Loeffler, Markus Scholz.

Resources: Markus Scholz.

Writing – original draft: Sibylle Schirm, Markus Scholz.

Writing – review & editing: Peter Ahnert, Sarah Berger, Geraldine Nouailles, Sandra-Maria Wienhold, Holger Müller-Redetzky, Norbert Suttorp, Markus Loeffler, Martin Witzzenrath.

References

1. World Health Organization: Pneumococcal disease; 2014.
2. Two Presentations at International Conferences of Preclinical Data on NOXXONs anti-C5a Spiegelmer, a Potential Drug in Pneumococcal Pneumonia-Induced Sepsis; 2014.
3. Müller-Redetzky HC, Kellermann U, Wienhold SM, Hellwig K, Gutbier B, Lienau J, et al. Neutralizing the complement component C5a protects against lung injury and extrapulmonary organ injury in pneumococcal pneumonia-induced sepsis. *Anesthesiology*. 2019; 132(4):795–807.
4. Hoehlig K, Maasch C, Shushakova N, Buchner K, Huber-Lang M, Purschke WG, et al. A Novel C5a-neutralizing Mirror-image (l-)Aptamer Prevents Organ Failure and Improves Survival in Experimental Sepsis. *Mol Ther*. 2013; 21(12):2236–2246. <https://doi.org/10.1038/mt.2013.178> PMID: 23887360
5. Schirm S, Ahnert P, Wienhold S, Mueller-Redetzky H, Nouailles-Kursar G, Loeffler M, et al. A Biomathematical Model of Pneumococcal Lung Infection and Antibiotic Treatment in Mice. *PLoS ONE*. 2016; 11(5)(6, e65630). <https://doi.org/10.1371/journal.pone.0156047> PMID: 27196107
6. Smith AM, McCullers JA, Adler FR. Mathematical Model of a Three-Stage Innate Immune Response to a Pneumococcal Lung Infection. *J Theor Biol*. 2011; 276(1):106–116. <https://doi.org/10.1016/j.jtbi.2011.01.052>
7. Pechous R. With Friends Like These: The Complex Role of Neutrophils in the Progression of Severe Pneumonia. Review. *Front Cell Infect Microbiol*. 2017; 7(160). <https://doi.org/10.3389/fcimb.2017.00160> PMID: 28507954
8. Meegan JE, Yang X, Coleman DC, Jannaway M, Yuan SY. Neutrophil-Mediated Vascular Barrier Injury: Role of Neutrophil Extracellular Traps. *Microcirculation*. 2017; 24(3). <https://doi.org/10.1111/micc.12352> PMID: 28120468
9. Crosby L, Waters C. Epithelial repair mechanisms in the lung. *Am J Physiol Lung Cell Mol Physiol*. 2010; 298(6):L715–L731. <https://doi.org/10.1152/ajplung.00361.2009>

10. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, et al. New perspectives on community-acquired pneumonia in 388 406 patients. *Thorax*. 2009; 64:1062–1069. <https://doi.org/10.1136/thx.2008.109785> PMID: 19454409
11. Angus D, Marrie T, Obrosky D, Clermont G, Dremsizov T, Coley C, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. *Am J Respir Crit Care Med*. 2002; 166(5):717–723. <https://doi.org/10.1164/rccm.2102084> PMID: 12204871
12. Fry D. Sepsis, Systemic Inflammatory Response, and Multiple Organ Dysfunction: The Mystery Continues. Review. *Am Surg*. 2012; 78(1):1–8. <https://doi.org/10.1177/000313481207800102>
13. Chow CC, Clermont G, Kumar R, Lagoa C, Tawadrous Z, Gallo D, et al. The acute inflammatory response in diverse shock states. *Shock*. 2005; 24(1):74–84. <https://doi.org/10.1097/01.shk.0000168526.97716.f3> PMID: 15988324
14. Yamamoto K, Ferrari JD, Cao Y, Ramirez MI, Jones MR, Quinton LJ, et al. Type I Alveolar Epithelial Cells Mount Innate Immune Responses during Pneumococcal Pneumonia. *J Immunol*. 2012; 189(5). <https://doi.org/10.4049/jimmunol.1200634> PMID: 22844121
15. Jones S. Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-6. *J Immunol*. 2005; 175:3463–3468. <https://doi.org/10.4049/jimmunol.175.6.3463>
16. Hartung D, Petrov A, Cheng K, Narula J. Tc-Monocyte chemoattractant protein-1. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). 2008 Feb 2 [updated 2008 Mar 26]; p. 2004–2013.
17. Zhang P, Summer W, Bagby G, Nelson S. Innate immunity and pulmonary host defense. *Immunol Rev*. 2000; 173:39–51. <https://doi.org/10.1034/j.1600-065X.2000.917306.x>
18. Stadnyk A. Cytokine production by epithelial cells. *FASEB J*. 1994; 8:1041–1047. <https://doi.org/10.1096/fasebj.8.13.7926369>
19. Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. *Biochimica et Biophysica Acta*. 2014; 1843:2563–2582. <https://doi.org/10.1016/j.bbamcr.2014.05.014>
20. Sky Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of interleukin-10. *Front Immunol*. 2013; 4(129).
21. Palomino D, Marti L. Chemokines and immunity. *einstein*. 2015; 13(3):469–473. <https://doi.org/10.1590/S1679-45082015RB3438>
22. Paudel S, Baral P, Ghimire L, Bergeron S, Jin L, DeCorte JA, et al. CXCL1 regulates neutrophil homeostasis in pneumonia-derived sepsis caused by *Streptococcus pneumoniae* serotype 3. *Blood*. 2019; 133(12):1335–1345. <https://doi.org/10.1182/blood-2018-10-878082> PMID: 30723078
23. Becker S, Quay J, Koren H, Haskill J. Constitutive and stimulated MCP-1, GRO alpha, beta, and gamma expression in human airway epithelium and bronchoalveolar macrophages. *Am J Physiol*. 1994; 266(3 Pt 1):L278–86.
24. Nouailles G, Dorhoi A, Koch M, Zerrahn J, Weiner J, Faé KC, et al. CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. *J Clin Invest*. 2014; 124(3):1268–1282. <https://doi.org/10.1172/JCI72030> PMID: 24509076
25. Jeyaseelan S, Manzer R, Young SK, Yamamoto M, Akira S, Mason RJ, et al. Induction of CXCL5 During Inflammation in the Rodent Lung Involves Activation of Alveolar Epithelium. *Am J Respir Cell Mol Biol*. 2005; 32(6):531–539. <https://doi.org/10.1165/rcmb.2005-0063OC> PMID: 15778492
26. Berger S, Goekeri C, Gupta SK, Vera J, Dietert K, Behrendt U, et al. Delay in antibiotic therapy results in fatal disease outcome in murine pneumococcal pneumonia. *Critical Care*. 2018; 22(287). <https://doi.org/10.1186/s13054-018-2224-5> PMID: 30382866
27. Müller-Redetzky HC, Wienhold SM, Berg J, Hocke AC, Hippenstiel S, Hellwig K, et al. Moxifloxacin is not anti-inflammatory in experimental pneumococcal pneumonia. *J Antimicrob Chemother*. 2015; 70(3):830–840. <https://doi.org/10.1093/jac/dku446> PMID: 25406299
28. Witznath M, Gutbier B, Schmeck B, Tenor H, Seybold J, Kuelzer R, et al. Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia. *Crit Care Med*. 2009; 37(2):584–590. <https://doi.org/10.1097/CCM.0b013e3181959814> PMID: 19114892
29. Rechenberg I. *Evolutionstrategie 94*. Stuttgart: Frommann-Holzboog; 1994.
30. Schwefel H. Evolution strategies: A family of nonlinear optimization techniques based on imitating some principles of organic evolution. *Ann Oper Res*. 1984; 1:65–167. <https://doi.org/10.1007/BF01876146>
31. Welte T, Dellinger RP, Ebel H, Ferrer M, Opal SM, Singer M, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). *Intensive Care Med*. 2018; 44:438–448. <https://doi.org/10.1007/s00134-018-5143-7> PMID: 29632995

32. Gutbier B, Jiang X, Dietert K, Ehrler C, Lienau J, Slyke PV, et al. Vasculotide reduces pulmonary hyper-permeability in experimental pneumococcal pneumonia. *Critical Care*. 2017; 21(274). <https://doi.org/10.1186/s13054-017-1851-6> PMID: 29132435
33. Mei J, Liu Y, Dai N, Favara M, Greene T, Jeyaseelan S, et al. CXCL5 regulates chemokine scavenging and pulmonary host defense to bacterial infection. *Immunity*. 2010; 33(1):106–117. <https://doi.org/10.1016/j.immuni.2010.07.009> PMID: 20643340
34. Pittet L, Quinton L, Yamamoto K, Robson B, Ferrari J, Algül H, et al. Earliest innate immune responses require macrophage RelA during pneumococcal pneumonia. *Am J Respir Cell Mol Biol*. 2011; 45(3):573–581. <https://doi.org/10.1165/rcmb.2010-0210OC> PMID: 21216972
35. Anevlavis S, Bouros D. Community acquired bacterial pneumonia. *Expert Opin Pharmacother*. 2010; 11(3):361–374. <https://doi.org/10.1517/14656560903508770>
36. Sweeney TE, Wong HR, Khatri P. Robust classification of bacterial and viral infections via integrated host gene expression diagnostics. *Sci Transl Med*. 2016; 8(364):1041–1047.
37. Boianelli A, Nguyen VK, Ebensen T, Schulze K, Wilk E, Sharma N, et al. Modeling Influenza Virus Infection: A Roadmap for Influenza Research. *Viruses*. 2015; 7(10):5274–304. <https://doi.org/10.3390/v7102875> PMID: 26473911
38. Figge M, Pollmächer J. Deciphering chemokine properties by a hybrid agent-based model of *Aspergillus fumigatus* infection in human alveoli. *Front Microbiol*. 2015; 6:503:1–14.
39. Pollmächer J, Figge M. Agent-based model of human alveoli predicts chemotactic signaling by epithelial cells during early *Aspergillus fumigatus* infection. *PLoS One*. 2014; 9(10):e111630. <https://doi.org/10.1371/journal.pone.0111630>
40. Diep JK, Russo TA, Rao GG. Mechanism-Based Disease Progression Model Describing Host-Pathogen Interactions During the Pathogenesis of *Acinetobacter baumannii* Pneumonia. *CPT Pharmacometrics Syst Pharmacol*. 2015; 6:503:1–14.
41. Mochan E, Swigon D, Ermentrout GB, Lukens S, Clermont G. A mathematical model of intrahost pneumococcal pneumonia infection dynamics in murine strains. *J Theor Biol*. 2014; 353:44–54. <https://doi.org/10.1016/j.jtbi.2014.02.021>
42. Domínguez-Hüttinger E, Boon NJ, Clarke TB, Tanaka RJ. Mathematical Modeling of *Streptococcus pneumoniae* Colonization, Invasive Infection and Treatment. *Front Physiol*. 2017; 8(115). <https://doi.org/10.3389/fphys.2017.00115> PMID: 28303104